Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Can J Physiol Pharmacol ; 96(5): 527-534, 2018 May.
Article in English | MEDLINE | ID: mdl-29505736

ABSTRACT

Transgenic mice constitutively overexpressing the cytokine transforming growth factor-ß1 (TGF-ß1) (TGF mice) display cerebrovascular alterations as seen in Alzheimer's disease (AD) and vascular cognitive impairment and dementia (VCID), but no or only subtle cognitive deficits. TGF-ß1 may exert part of its deleterious effects through interactions with angiotensin II (AngII) type 1 receptor (AT1R) signaling pathways. We test such interactions in the brain and cerebral vessels of TGF mice by measuring cerebrovascular reactivity, levels of protein markers of vascular fibrosis, nitric oxide synthase activity, astrogliosis, and mnemonic performance in mice treated (6 months) with the AT1R blocker losartan (10 mg/kg per day) or the angiotensin converting enzyme inhibitor enalapril (3 mg/kg per day). Both treatments restored the severely impaired cerebrovascular reactivity to acetylcholine, calcitonin gene-related peptide, endothelin-1, and the baseline availability of nitric oxide in aged TGF mice. Losartan, but not enalapril, significantly reduced astrogliosis and cerebrovascular levels of profibrotic protein connective tissue growth factor while raising levels of antifibrotic enzyme matrix metallopeptidase-9. Memory was unaffected by aging and treatments. The results suggest a pivotal role for AngII in TGF-ß1-induced cerebrovascular dysfunction and neuroinflammation through AT1R-mediated mechanisms. Further, they suggest that AngII blockers could be appropriate against vasculopathies and astrogliosis associated with AD and VCID.


Subject(s)
Brain/blood supply , Gliosis/pathology , Gliosis/physiopathology , Receptor, Angiotensin, Type 1/metabolism , Signal Transduction , Transforming Growth Factor beta1/metabolism , Animals , Brain/drug effects , Enalapril/pharmacology , Enalapril/therapeutic use , Female , Fibrosis , Gliosis/metabolism , Losartan/pharmacology , Losartan/therapeutic use , Male , Mice , Mice, Transgenic , Signal Transduction/drug effects
2.
Histochem Cell Biol ; 147(5): 585-593, 2017 May.
Article in English | MEDLINE | ID: mdl-28220244

ABSTRACT

The renal tissular renin-angiotensin and bradykinin-kallikrein systems control kidney function together with the renal sympathetic innervation but their interaction is still unclear. To further elucidate this relationship, we investigated these systems in rats 6 days after left kidney denervation (DNX, n = 8) compared to sham-operated controls (CTR, n = 8). Plasma renin concentration was unchanged in DNX vs. CTR (p = NS). Kidney bradykinin (BK) and angiotensin (Ang) I and II concentrations decreased bilaterally in DNX vs. CTR rats (~20 to 40%, p < 0.05) together with Ang IV and V concentrations that were extremely low (p = NS). Renin, Ang III and dopamine concentrations decreased by ~25 to 50% and norepinephrine concentrations by 99% in DNX kidneys (p < 0.05) but were unaltered in opposite kidneys. Ang II/I and KA were comparable in DNX, contralateral and CTR kidneys. Ang III/II increased in right vs. DNX or CTR kidneys (40-50%, p < 0.05). Ang II was mainly located in tubular epithelium by immunocytological staining and its cellular distribution was unaffected by DNX. Moreover, the angiotensinergic and catecholaminergic innervation of right kidneys was unchanged vs. CTR. We found an important dependency of tissular Ang and BK levels on the renal innervation that may contribute to the resetting of kidney function after DNX. The DNX-induced peptide changes were not readily explained by kidney KA, renin or plasma Ang I generation. However, tissular peptide metabolism and compartmentalization may have played a central role. The mechanisms behind the concentration changes remain unclear and deserve further clarification.


Subject(s)
Angiotensins/metabolism , Bradykinin/metabolism , Denervation , Kallikreins/metabolism , Kidney/innervation , Kidney/metabolism , Renin/metabolism , Animals , Kidney/surgery , Male , Rats , Rats, Wistar
3.
Neurobiol Dis ; 68: 126-36, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24807206

ABSTRACT

Angiotensin II (AngII) receptor blockers that bind selectively AngII type 1 (AT1) receptors may protect from Alzheimer's disease (AD). We studied the ability of the AT1 receptor antagonist losartan to cure or prevent AD hallmarks in aged (~18months at endpoint, 3months treatment) or adult (~12months at endpoint, 10months treatment) human amyloid precursor protein (APP) transgenic mice. We tested learning and memory with the Morris water maze, and evaluated neurometabolic and neurovascular coupling using [(18)F]fluoro-2-deoxy-D-glucose-PET and laser Doppler flowmetry responses to whisker stimulation. Cerebrovascular reactivity was assessed with on-line videomicroscopy. We measured protein levels of oxidative stress enzymes (superoxide dismutases SOD1, SOD2 and NADPH oxidase subunit p67phox), and quantified soluble and deposited amyloid-ß (Aß) peptide, glial fibrillary acidic protein (GFAP), AngII receptors AT1 and AT2, angiotensin IV receptor AT4, and cortical cholinergic innervation. In aged APP mice, losartan did not improve learning but it consolidated memory acquisition and recall, and rescued neurovascular and neurometabolic coupling and cerebrovascular dilatory capacity. Losartan normalized cerebrovascular p67phox and SOD2 protein levels and up-regulated those of SOD1. Losartan attenuated astrogliosis, normalized AT1 and AT4 receptor levels, but failed to rescue the cholinergic deficit and the Aß pathology. Given preventively, losartan protected cognitive function, cerebrovascular reactivity, and AT4 receptor levels. Like in aged APP mice, these benefits occurred without a decrease in soluble Aß species or plaque load. We conclude that losartan exerts potent preventive and restorative effects on AD hallmarks, possibly by mitigating AT1-initiated oxidative stress and normalizing memory-related AT4 receptors.


Subject(s)
Alzheimer Disease/complications , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Cerebrovascular Circulation/drug effects , Cognition Disorders/drug therapy , Cognition Disorders/etiology , Losartan/therapeutic use , Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Arginine/analogs & derivatives , Arginine/pharmacology , Blood Pressure/drug effects , Blood Pressure/genetics , Brain/drug effects , Brain/metabolism , Brain/pathology , Cognition Disorders/pathology , Disease Models, Animal , Endothelin-1/pharmacology , Enzyme Inhibitors/pharmacology , Female , Gene Expression Regulation/drug effects , Humans , Losartan/pharmacology , Male , Mice , Mice, Transgenic , Mutation/genetics
4.
Curr Hypertens Rep ; 15(1): 10-6, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23197298

ABSTRACT

Intrarenal neurotransmission implies the co-release of neuropeptides at the neuro-effector junction with direct influence on parameters of kidney function. The presence of an angiotensin (Ang) II-containing phenotype in catecholaminergic postganglionic and sensory fibers of the kidney, based on immunocytological investigations, has only recently been reported. These angiotensinergic fibers display a distinct morphology and intrarenal distribution, suggesting anatomical and functional subspecialization linked to neuronal Ang II-expression. This review discusses the present knowledge concerning these fibers, and their significance for renal physiology and the pathogenesis of hypertension in light of established mechanisms. The data suggest a new role of Ang II as a co-transmitter stimulating renal target cells or modulating nerve traffic from or to the kidney. Neuronal Ang II is likely to be an independent source of intrarenal Ang II. Further physiological experimentation will have to explore the role of the angiotensinergic renal innervation and integrate it into existing concepts.


Subject(s)
Angiotensin II/physiology , Kidney/innervation , Kidney/physiology , Animals , Autonomic Nervous System/physiology , Endothelium, Vascular/physiology , Humans , Hypertension/metabolism , Immunohistochemistry , Kidney/metabolism , Neuroeffector Junction/physiology , Neurons/chemistry , Neuropeptides/physiology , Synaptic Transmission/physiology
5.
J Immunol ; 185(10): 6286-93, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20935205

ABSTRACT

Emerging evidence suggests a cardioprotective role of the angiotensin AT2R, albeit the underlying cellular mechanisms are not well understood. We aimed in this article to elucidate a potential role of cardiac angiotensin AT2R in regulating cellular immune response to ischemic heart injury. Seven days after myocardial infarction in rats, double-immunofluorescence staining showed that AT2R was detected in a fraction of CD8(+) T cells infiltrating in the peri-infarct myocardium. We developed a method that allowed the isolation of myocardial infiltrating CD8(+)AT2R(+) T cells using modified MACS, and further characterization and purification with flow cytometry. Although the CD8(+)AT2R(-) T cells exhibited potent cytotoxicity to both adult and fetal cardiomyocytes (CMs), the CD8(+)AT2R(+) T cells were noncytotoxic to these CMs. The CD8(+)AT2R(+) T cells were characterized by upregulated IL-10 and downregulated IL-2 and INF-γ expression when compared with CD8(+)AT2R(-) T cells. We further showed that IL-10 gene expression was enhanced in CD8(+) T cells on in vitro AT2R stimulation. Importantly, in vivo AT2R activation engendered an increment of CD8(+)AT2R(+) T cells and IL-10 production in the ischemic myocardium. In addition, intramyocardial transplantation of CD8(+)AT2R(+) T cells (versus CD8(+)AT2R(-)) led to reduced ischemic heart injury. Moreover, the CD8(+)AT2R(+) T cell population was also demonstrated in human peripheral blood. Thus, we have defined the cardioprotective CD8(+)AT2R(+) T cell population, which increases during ischemic heart injury and contributes to maintaining CM viability and providing IL-10, hence revealing an AT2R-mediated cellular mechanism in modulating adaptive immune response in the heart.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Interleukin-10/biosynthesis , Myocardial Infarction/immunology , Myocardium/immunology , Receptor, Angiotensin, Type 2/immunology , T-Lymphocyte Subsets/metabolism , Animals , CD8-Positive T-Lymphocytes/metabolism , Cell Separation/methods , Flow Cytometry/methods , Fluorescent Antibody Technique , Gene Expression , Interleukin-10/immunology , Male , Myocardial Infarction/metabolism , Myocardial Ischemia/immunology , Myocardial Ischemia/metabolism , Myocardium/metabolism , Myocardium/pathology , Rats , Rats, Wistar , Receptor, Angiotensin, Type 2/metabolism , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocyte Subsets/immunology
6.
Hum Mol Genet ; 18(3): 546-55, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-19010792

ABSTRACT

In spinal muscular atrophy (SMA), the leading genetic cause of early childhood death, the survival motor neuron 1 gene (SMN1) is deleted or inactivated. The nearly identical SMN2 gene has a silent mutation that impairs the utilization of exon 7 and the production of functional protein. It has been hypothesized that therapies boosting SMN2 exon 7 inclusion might prevent or cure SMA. Exon 7 inclusion can be stimulated in cell culture by oligonucleotides or intracellularly expressed RNAs, but evidence for an in vivo improvement of SMA symptoms is lacking. Here, we unambiguously confirm the above hypothesis by showing that a bifunctional U7 snRNA that stimulates exon 7 inclusion, when introduced by germline transgenesis, can efficiently complement the most severe mouse SMA model. These results are significant for the development of a somatic SMA therapy, but may also provide new means to study pathophysiological aspects of this devastating disease.


Subject(s)
Genetic Therapy , Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/therapy , RNA, Small Nuclear/therapeutic use , Animals , Base Sequence , Exons , Humans , Mice , Mice, Transgenic , Molecular Sequence Data , Muscular Atrophy, Spinal/metabolism , RNA Splicing , RNA, Small Nuclear/genetics , Survival of Motor Neuron 2 Protein/genetics , Survival of Motor Neuron 2 Protein/metabolism
7.
Cell Tissue Res ; 341(1): 181-95, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20526894

ABSTRACT

The angiotensins constitute a neuropeptidergic system that emerged early in evolution. Their classical osmoregulatory and dipsogenic functions and their mnemonic actions have been demonstrated both in vertebrates and in some invertebrates. Previously, we have shown that, in the euryhaline and semiterrestrial crab Chasmagnathus granulatus, water deprivation correlates with an increased level of brain angiotensin-II-like neuropeptide/s (ANGII-like) and improves memory processes through ANGII receptors. We have proposed that the release of brain angiotensins in response to water shortages is an ancient mechanism for coordinating various functions that, together, enable organisms to tolerate this environmental change. Here, we have evaluated the physiological changes in ANGII-like levels in diverse structures of the central nervous system of these animals during water deprivation. The neuroanatomical distribution of ANGII-like is described in the optic lobes and brain of Chasmagnathus granulatus and the physiological changes in ANGII-like distribution in various brain neuropils is evaluated after water deprivation. Our results indicate that ANGII-like is widely distributed, especially in the medial protocerebrum. After 2 h of water deprivation, ANGII-like immunoreactivity increases in the central body and decreases in the olfactory neuropil and, after 6 h of water deprivation, is markedly reduced in several brain areas. Although further experiments are needed to establish that the angiotensinergic system is involved in the balance of body fluids in this crab, our results suggest that ANGII regulates several functions during water shortages.


Subject(s)
Angiotensin II/metabolism , Brachyura/anatomy & histology , Brachyura/physiology , Central Nervous System/anatomy & histology , Central Nervous System/physiology , Water Deprivation/physiology , Animals , Brachyura/cytology , Brain/anatomy & histology , Brain/physiology , Central Nervous System/cytology , Immunohistochemistry , Male , Optic Lobe, Nonmammalian/anatomy & histology , Optic Lobe, Nonmammalian/physiology , Protein Transport
8.
Stem Cells ; 27(10): 2488-97, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19591228

ABSTRACT

The expression pattern of angiotensin AT2 receptors with predominance during fetal life and upregulation under pathological conditions during tissue injury/repair process suggests that AT2 receptors may exert an important action in injury/repair adaptive mechanisms. Less is known about AT2 receptors in acute ischemia-induced cardiac injury. We aimed here to elucidate the role of AT2 receptors after acute myocardial infarction. Double immunofluorescence staining showed that cardiac AT2 receptors were mainly detected in clusters of small c-kit+ cells accumulating in peri-infarct zone and c-kit+AT2+ cells increased in response to acute cardiac injury. Further, we isolated cardiac c-kit+AT2+ cell population by modified magnetic activated cell sorting and fluorescence activated cell sorting. These cardiac c-kit+AT2+ cells, represented approximately 0.19% of total cardiac cells in infarcted heart, were characterized by upregulated transcription factors implicated in cardiogenic differentiation (Gata-4, Notch-2, Nkx-2.5) and genes required for self-renewal (Tbx-3, c-Myc, Akt). When adult cardiomyocytes and cardiac c-kit+AT2+ cells isolated from infarcted rat hearts were cocultured, AT2 receptor stimulation in vitro inhibited apoptosis of these cocultured cardiomyocytes. Moreover, in vivo AT2 receptor stimulation led to an increased c-kit+AT2+ cell population in the infarcted myocardium and reduced apoptosis of cardiomyocytes in rats with acute myocardial infarction. These data suggest that cardiac c-kit+AT2+ cell population exists and increases after acute ischemic injury. AT2 receptor activation supports performance of cardiomyocytes, thus contributing to cardioprotection via cardiac c-kit+AT2+ cell population.


Subject(s)
Myocardial Ischemia/metabolism , Myocytes, Cardiac/metabolism , Proto-Oncogene Proteins c-kit/metabolism , Receptor, Angiotensin, Type 2/metabolism , Regeneration/physiology , Stem Cells/metabolism , Angiotensins/metabolism , Angiotensins/pharmacology , Animals , Cardiotonic Agents/metabolism , Cardiotonic Agents/pharmacology , Cell Differentiation/physiology , Cell Proliferation/drug effects , Cells, Cultured , Cytoprotection/drug effects , Cytoprotection/physiology , Flow Cytometry , Fluorescent Antibody Technique , Male , Myocardial Ischemia/physiopathology , Myocytes, Cardiac/cytology , Rats , Rats, Wistar , Signal Transduction/physiology , Stem Cells/cytology , Transcription Factors/metabolism
9.
Regul Pept ; 154(1-3): 23-31, 2009 Apr 10.
Article in English | MEDLINE | ID: mdl-19323983

ABSTRACT

To clarify the role of Angiotensin II (Ang II) in the sensory system and especially in the trigeminal ganglia, we studied the expression of angiotensinogen (Ang-N)-, renin-, angiotensin converting enzyme (ACE)- and cathepsin D-mRNA, and the presence of Ang II and substance P in the rat and human trigeminal ganglia. The rat trigeminal ganglia expressed substantial amounts of Ang-N- and ACE mRNA as determined by quantitative real time PCR. Renin mRNA was untraceable in rat samples. Cathepsin D was detected in the rat trigeminal ganglia indicating the possibility of existence of pathways alternative to renin for Ang I formation. In situ hybridization in rat trigeminal ganglia revealed expression of Ang-N mRNA in the cytoplasm of numerous neurons. By using immunocytochemistry, a number of neurons and their processes in both the rat and human trigeminal ganglia were stained for Ang II. Post in situ hybridization immunocytochemistry reveals that in the rat trigeminal ganglia some, but not all Ang-N mRNA-positive neurons marked for Ang II. In some neurons Substance P was found colocalized with Ang II. Angiotensins from rat trigeminal ganglia were quantitated by radioimmunoassay with and without prior separation by high performance liquid chromatography. Immunoreactive angiotensin II (ir-Ang II) was consistently present and the sum of true Ang II (1-8) octapeptide and its specifically measured metabolites were found to account for it. Radioimmunological and immunocytochemical evidence of ir-Ang II in neuronal tissue is compatible with Ang II as a neurotransmitter. In conclusion, these results suggest that Ang II could be produced locally in the neurons of rat trigeminal ganglia. The localization and colocalization of neuronal Ang II with Substance P in the trigeminal ganglia neurons may be the basis for a participation and function of Ang II in the regulation of nociception and migraine pathology.


Subject(s)
Angiotensinogen/analysis , Angiotensinogen/metabolism , Neurons/metabolism , Trigeminal Ganglion/metabolism , Adult , Angiotensin I/analysis , Angiotensin II/analysis , Angiotensinogen/genetics , Animals , Humans , Immunohistochemistry , In Situ Hybridization , Male , RNA, Messenger/metabolism , Radioimmunoassay , Rats , Rats, Inbred WKY
10.
J Neuroendocrinol ; 31(4): e12703, 2019 04.
Article in English | MEDLINE | ID: mdl-30803087

ABSTRACT

Angiotensin II (Ang II) acts on Ang II type 1 (AT1) receptors located in the organum vasculosum and subfornical organ (SFO) of the lamina terminalis as a main facilitatory mechanism of sodium appetite. The brain serotonin (5-HT) system with soma located in the dorsal raphe nucleus (DRN) provides a main inhibitory mechanism. In the present study, we first investigated the existence of Ang II AT1 receptors in serotonergic DRN neurones. Then, we examined whether whole body sodium depletion affects the gene expression of the AT1a receptor subtype and the presumed functional significance of AT1 receptors. Using confocal microscopy, we found that tryptophan hydroxylase-2 and serotonin neurones express AT1 receptors in the DRN. Immunofluorescence quantification showed a significant reduction in 5-HT content but no change in AT1 receptor expression or AT1/5-HT colocalisation in the DRN after sodium depletion. Whole body sodium depletion also significantly increased Agtr1a mRNA expression in the SFO and DRN. Oral treatment with the AT1 receptor antagonist losartan reversed the changes in Agtr1a expression in the SFO but not the DRN. Losartan injection into either the DRN or the mesencephalic aqueduct had no influence on sodium depletion-induced 0.3 mol L-1 NaCl intake. The results indicate the expression of Agtr1a mRNA in the DRN and SFO as a marker of sodium depletion. They also suggest that serotonergic DRN neurones are targets for Ang II. However, the function of their AT1 receptors remains elusive.


Subject(s)
Dorsal Raphe Nucleus/metabolism , Gene Expression , Receptor, Angiotensin, Type 1/genetics , Serotonin/analysis , Sodium/deficiency , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Appetite/physiology , Dorsal Raphe Nucleus/chemistry , Fluorescent Antibody Technique , Gene Expression/physiology , Losartan/pharmacology , Male , Neurons/chemistry , RNA, Messenger/analysis , Rats , Rats, Wistar , Receptor, Angiotensin, Type 1/analysis , Receptor, Angiotensin, Type 1/physiology , Sodium/blood , Subfornical Organ/chemistry , Subfornical Organ/metabolism , Tryptophan Hydroxylase/analysis
11.
Regul Pept ; 147(1-3): 82-7, 2008 Apr 10.
Article in English | MEDLINE | ID: mdl-18308407

ABSTRACT

In contrast to the current belief that angiotensin II (Ang II) interacts with the sympathetic nervous system only as a circulating hormone, we document here the existence of endogenous Ang II in the neurons of rat and human sympathetic coeliac ganglia and their angiotensinergic innervation with mesenteric resistance blood vessels. Angiotensinogen - and angiotensin converting enzyme-mRNA were detected by using quantitative real time polymerase chain reaction in total RNA extracts of rat coeliac ganglia, while renin mRNA was untraceable. Cathepsin D, a protease responsible for cleavage beneath other substrates also angiotensinogen to angiotensin I, was successfully detected in rat coeliac ganglia indicating the possibility of existence of alternative pathways. Angiotensinogen mRNA was also detected by in situ hybridization in the cytoplasm of neurons of rat coeliac ganglia. Immunoreactivity for Ang II was demonstrated in rat and human coeliac ganglia as well as with mesenteric resistance blood vessels. By using confocal laser scanning microscopy we were able to demonstrate the presence of angiotensinergic synapses en passant along side of vascular smooth muscle cells. Our findings indicate that Ang II is synthesized inside the neurons of sympathetic coeliac ganglia and may act as an endogenous neurotransmitter locally with the mesenteric resistance blood vessels.


Subject(s)
Angiotensinogen/metabolism , Ganglia, Sympathetic/metabolism , Mesenteric Arteries/innervation , Neurons/metabolism , Angiotensinogen/genetics , Animals , Humans , Immunohistochemistry , Male , RNA, Messenger/metabolism , Rats , Rats, Inbred WKY , Renin-Angiotensin System/physiology , Reverse Transcriptase Polymerase Chain Reaction
12.
Am J Hypertens ; 31(2): 188-196, 2018 01 12.
Article in English | MEDLINE | ID: mdl-28985343

ABSTRACT

BACKGROUND: The right atrium is densely innervated and provides sensory input to important cardiocirculatory reflexes controlling cardiac output and blood pressure. Its angiotensin (Ang) II-expressing innervation may release Ang II as a neuropeptide cotransmitter to modulate reflexes but has not yet been characterized. METHODS: Intraoperative surgical biopsies from human right atria (n = 7) were immunocytologically stained for Ang II, tyrosine hydroxylase (TH), and synaptophysin (SYN). Tissue angiotensins were extracted and quantified by radioimmunoassay. RESULTS: Angiotensinergic fibers were frequent in epicardial nerves and around vessels with variable TH co-localization (none to >50%/bundle). Fibers were also widely distributed between cardiomyocytes and in the endocardium where they were typically nonvaricose, TH/SYN-negative and usually accompanied by varicose catecholaminergic fibers. In the endocardium, some showed large varicosities and were partially TH or SYN-positive. A few endocardial regions showed scattered nonvaricose Ang fibers ending directly between endothelial cells. Occasional clusters of thin varicose terminals co-localizing SYN or TH were located underneath, or protruded into, the endothelium. Endocardial density of Ang and TH-positive fibers was 30-300 vs. 200-450/mm2. Atrial Ang II, III, and I concentrations were 67, 16, and 5 fmol/g (median) while Ang IV and V were mostly undetectable. CONCLUSIONS: The human right atrium harbors an abundant angiotensinergic innervation and a novel potential source of atrial Ang II. Most peripheral fibers were noncatecholaminergic afferents or preterminal vagal efferents and a minority was presumably sympathetic. Neuronal Ang II release from these fibers may modulate cardiac and circulatory reflexes independently from plasma and tissue Ang II sources.


Subject(s)
Angiotensin II/analysis , Autonomic Nervous System/chemistry , Heart Atria/innervation , Nerve Fibers/chemistry , Reflex , Aged , Angiotensin I/analysis , Angiotensin II/analogs & derivatives , Angiotensin III/analysis , Angiotensins/analysis , Humans , Male , Middle Aged , Peptide Fragments/analysis , Synaptophysin/analysis , Tyrosine 3-Monooxygenase/analysis
13.
J Cereb Blood Flow Metab ; 37(6): 1959-1970, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27389178

ABSTRACT

Alterations of the renin-angiotensin system have been implicated in the pathogenesis of Alzheimer's disease. We tested the efficacy of losartan (10 mg/kg/day for three months), a selective angiotensin II type 1 receptor antagonist, in alleviating cerebrovascular and cognitive deficits in double-transgenic mice (six months at endpoint) that overexpress a mutated form of the human amyloid precursor protein (APPSwe,Ind) and a constitutively active form of the transforming growth factor-ß1, thereafter named A/T mice. Losartan rescued cerebrovascular reactivity, particularly the dilatory responses, but failed to attenuate astroglial activation and to normalize the neurovascular uncoupling response to sensory stimulation. The cognitive deficits of A/T mice were not restored by losartan nor were the increased brain levels of soluble and insoluble Aß1-40 and Aß1-42 peptides normalized. Our results are the first to demonstrate the capacity of losartan to improve cerebrovascular reactivity in an Alzheimer's disease mouse model of combined Aß-induced vascular oxidative stress and transforming growth factor-ß1-mediated vascular fibrosis. These data suggest that losartan may be promising for restoring cerebrovascular function in patients with vascular diseases at risk for vascular dementia or Alzheimer's disease. However, a combined therapy may be warranted for rescuing both vascular and cognitive deficits in a multifaceted pathology like Alzheimer's disease.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/biosynthesis , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Cerebrovascular Circulation/drug effects , Losartan/therapeutic use , Transforming Growth Factor beta1/biosynthesis , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/genetics , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Animals , Blood Flow Velocity/drug effects , Blood Pressure/drug effects , Humans , Losartan/administration & dosage , Maze Learning/drug effects , Memory/drug effects , Mice, Inbred C57BL , Mice, Transgenic , Oxidative Stress/drug effects , Renin-Angiotensin System/drug effects , Transforming Growth Factor beta1/genetics
14.
Sci Rep ; 7: 39988, 2017 01 04.
Article in English | MEDLINE | ID: mdl-28051180

ABSTRACT

Cardiac tissue engineering using biomaterials with or without combination of stem cell therapy offers a new option for repairing infarcted heart. However, the bioactivity of biomaterials remains to be optimized because currently available biomaterials do not mimic the biochemical components as well as the structural properties of native myocardial extracellular matrix. Here we hypothesized that human heart valve-derived scaffold (hHVS), as a clinically relevant novel biomaterial, may provide the proper microenvironment of native myocardial extracellular matrix for cardiac repair. In this study, human heart valve tissue was sliced into 100 µm tissue sheet by frozen-sectioning and then decellularized to form the hHVS. Upon anchoring onto the hHVS, post-infarct murine BM c-kit+ cells exhibited an increased capacity for proliferation and cardiomyogenic differentiation in vitro. When used to patch infarcted heart in a murine model of myocardial infarction, either implantation of the hHVS alone or c-kit+ cell-seeded hHVS significantly improved cardiac function and reduced infarct size; while c-kit+ cell-seeded hHVS was even superior to the hHVS alone. Thus, we have successfully developed a hHVS for cardiac repair. Our in vitro and in vivo observations provide the first clinically relevant evidence for translating the hHVS-based biomaterials into clinical strategies to treat myocardial infarction.


Subject(s)
Bone Marrow Cells/physiology , Mitral Valve/physiology , Myocardial Infarction/therapy , Tissue Engineering/methods , Tissue Scaffolds , Animals , Biocompatible Materials , Bone Marrow Cells/ultrastructure , Cell Differentiation , Cell Proliferation , Cells, Cultured , Disease Models, Animal , Humans , Male , Mice, Inbred C57BL , Mitral Valve/ultrastructure
15.
Stroke ; 37(5): 1271-6, 2006 May.
Article in English | MEDLINE | ID: mdl-16601219

ABSTRACT

BACKGROUND AND PURPOSE: Blockade of angiotensin II AT1 receptors in cerebral microvessels protects against brain ischemia and inflammation. In this study, we tried to clarify the presence and regulation of the local renin-angiotensin system (RAS) in brain microvessels in hypertension. METHODS: Spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) controls were treated with an AT1 receptor antagonist (candesartan, 0.3 mg/kg per day) via subcutaneous osmotic minipumps for 4 weeks. The expression and localization of RAS components and the effect of AT1 receptor blockade were assessed by Affymetrix microarray, qRT-PCR, Western blots, immunohistochemistry and immunofluorescence. RESULTS: We found transcripts of most of RAS components in our microarray database, and confirmed their expression by qRT-PCR. Angiotensinogen (Aogen), angiotensin-converting enzyme (ACE) and AT1 receptors were localized to the endothelium. There was no evidence of AT2 receptor localization in the microvascular endothelium. In SHR, (pro)renin receptor mRNA and AT1 receptor mRNA and protein expression were higher, whereas Aogen, ACE mRNA and AT2 receptor mRNA and protein expression were lower than in WKY rats. Candesartan treatment increased Aogen, ACE and AT2 receptor in SHR, and increased ACE and decreased Aogen in WKY rats, without affecting the (pro)renin and AT1 receptors. CONCLUSIONS: Increased (pro)renin and AT1 receptor expression in SHR substantiates the importance of the local RAS overdrive in the cerebrovascular pathophysiology in hypertension. AT1 receptor blockade and increased AT2 receptor stimulation after administration of candesartan may contribute to the protection against brain ischemia and inflammation.


Subject(s)
Angiotensin II/metabolism , Brain/blood supply , Hypertension/metabolism , Microcirculation/metabolism , Receptor, Angiotensin, Type 1/metabolism , Signal Transduction , Angiotensin II/antagonists & inhibitors , Angiotensin II/genetics , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Benzimidazoles/pharmacology , Biphenyl Compounds , Gene Expression Regulation , Hypertension/physiopathology , Male , Microcirculation/physiopathology , Rats , Rats, Inbred SHR , Receptor, Angiotensin, Type 1/genetics , Renin-Angiotensin System/genetics , Signal Transduction/drug effects , Tetrazoles/pharmacology
16.
In Vitro Cell Dev Biol Anim ; 42(7): 189-200, 2006.
Article in English | MEDLINE | ID: mdl-16948500

ABSTRACT

In the proximal convoluted tubule (PCT) angiotensin II (Ang II) modulates fluid and electrolyte transport through at least two pharmacologically distinct receptor subtypes: AT(1) and AT(2). Development of cell lines that lack these receptors are potentially useful models to probe the complex cellular details of Ang II regulation. To this end, angiotensin receptor- deficient mice were bred with an Immortomouse(R), which harbors a thermolabile SV40 large-T antigen (Tag). S1 PCT segments from kidneys of F(2) mice were microdissected, placed in culture, and maintained under conditions that enhanced cell growth, i.e., promoted Tag expression and thermostability. Three different types of angiotensin receptor-deficient cell lines, (AT(1A) [-/-], Tag [+/-]), (AT(1B) [-/-], Tag [+/-]), and (AT(1A) [-/-], AT(1B) [-/-], Tag [+/+]), as well as wild type cell lines were generated. Screening and characterization, which were conducted under culture conditions that promoted cellular differentiation, included: measurements of transepithelial transport, such as basal monolayer short-circuit current (Isc; -3 to 3 microA/cm2), basal monolayer conductance (G, 2 to 10 mS/cm2), Na3(+)-phosphate cotransport (DeltaIsc of 2 to 3 microA/cm(2) at 1 mM), and Na(3)(+)-succinate cotransport (DeltaIsc of 1 to 9 microA/cm(2) at 2 mM). Morphology of cell monolayers showed an extensive brush border, well-defined tight junctions, and primary cilia. Receptor functionality was assessed by Ang II-stimulated beta-arrestin 2 translocation and showed an Ang II-mediated response in wild type but not (AT(1A) [-/ -], AT(1B) [-/-]) cells. Cell lines were amplified, yielding a virtually unlimited supply of highly differentiated, transport-competent, angiotensin receptor-deficient PCT cell lines.


Subject(s)
Cell Culture Techniques , Cell Line , Kidney Tubules, Proximal/cytology , Receptors, Angiotensin/genetics , Angiotensin II/genetics , Angiotensin II/metabolism , Animals , Arrestins/metabolism , Biological Transport/physiology , Breeding , Cell Differentiation , Electrolytes/metabolism , Genotype , Immunohistochemistry , Kidney Tubules, Proximal/metabolism , Mice , Mutation , RNA, Messenger/metabolism , Receptors, Angiotensin/metabolism , beta-Arrestin 2 , beta-Arrestins
17.
J Alzheimers Dis ; 51(4): 1183-95, 2016.
Article in English | MEDLINE | ID: mdl-26923013

ABSTRACT

The co-administration of angiotensin converting enzyme inhibitors (ACEi) and angiotensin II (AngII) receptor blockers (ARB) that bind angiotensin type 1 receptors (AT1R) may protect from Alzheimer's disease (AD) better than each treatment taken alone. We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-ß protein precursor (AßPP, thereafter APP mice). We studied cerebrovascular function, protein levels of oxidative stress markers (superoxide dismutases SOD1, SOD2 and the NADPH oxidase subunit p67phox), amyloid-ß (Aß) pathology, astrogliosis, cholinergic innervation, AT1R and angiotensin IV receptor (AT4R) levels, together with cognitive performance. Both treatments normalized cerebrovascular reactivity and p67phox protein levels, but they did not reduce the cerebrovascular levels of SOD1. Combined treatment normalized cerebrovascular SOD2 levels, significantly attenuated astrogliosis, but did not reduce the increased levels of cerebrovascular AT1R. Yet, combined therapy enhanced thioflavin-S labeled Aß plaque burden, a tendency not significant when Aß1 - 42 plaque load was considered. None of the treatments rescued cognitive deficits, cortical AT4R or cholinergic innervation. We conclude that both treatments normalized cerebrovascular function by inhibiting the AngII-induced oxidative stress cascade, and that the positive effects of the combined therapy on astrogliosis were likely due to the ability of losartan to enter brain parenchyma. However, enalapril did not potentiate, and may even dampen, the reported cognitive benefits of losartan, raising caution when selecting the most appropriate antihypertensive therapy in AD patients.


Subject(s)
Alzheimer Disease/complications , Antihypertensive Agents/therapeutic use , Cerebrovascular Disorders/drug therapy , Cerebrovascular Disorders/etiology , Enalapril/therapeutic use , Losartan/therapeutic use , Alzheimer Disease/genetics , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Amyloidosis/drug therapy , Amyloidosis/etiology , Analysis of Variance , Animals , Cholinesterases/metabolism , Disease Models, Animal , Drug Combinations , Female , Glial Fibrillary Acidic Protein/metabolism , Humans , Male , Maze Learning/drug effects , Memory Disorders/drug therapy , Memory Disorders/etiology , Mice , Mice, Transgenic , Mutation/genetics
18.
J Mol Histol ; 36(1-2): 77-87, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15704002

ABSTRACT

HTm4 is a member of a newly defined family of human and murine proteins, the MS4 (membrane-spanning four) protein group, which has a distinctive four-transmembrane structure. MS4 protein functions include roles as cell surface signaling receptors and intracellular adapter proteins. We have previously demonstrated that HTm4 regulates the function of the KAP phosphatase, a key regulator of cell cycle progression. In humans, the expression of HTm4 is largely restricted to cells of the hematopoietic lineage, possibly reflecting a causal role for this molecule in differentiation/proliferation of hematopoietic lineage cells. In this study, we show that, like the human homologue, murine HTm4 is also predominantly a hematopoietic protein with distinctive expression patterns in developing murine embryos and in adult animals. In addition, we observed that murine HTm4 is highly expressed in the developing and adult murine nervous system, suggesting a previously unrecognized role in central and peripheral nervous system development.


Subject(s)
Cell Cycle Proteins/metabolism , Central Nervous System/embryology , Hematopoietic System/embryology , Membrane Proteins/metabolism , Amino Acid Sequence , Animals , Base Sequence , Cell Cycle/physiology , Cell Cycle Proteins/analysis , Cell Cycle Proteins/genetics , Cell Differentiation , Central Nervous System/cytology , Central Nervous System/metabolism , Embryo, Mammalian/cytology , Hematopoietic Stem Cells/chemistry , Hematopoietic System/cytology , Hematopoietic System/metabolism , Membrane Proteins/analysis , Membrane Proteins/genetics , Mice , Molecular Sequence Data , Neurons/chemistry , Protein Conformation , RNA, Messenger/analysis , RNA, Messenger/metabolism
19.
Peptides ; 26(7): 1270-7, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15949646

ABSTRACT

Biochemical analysis revealed that angiotensin-converting enzyme related carboxy-peptidase (ACE2) cleaves angiotensin (Ang) II to Ang-(1-7), a heptapeptide identified as an endogenous ligand for the G protein-coupled receptor Mas. No data are currently available that systematically describe ACE2 distribution and activity in rodents. Therefore, we analyzed the ACE2 expression in different tissues of mice and rats on mRNA (RNase protection assay) and protein levels (immunohistochemistry, ACE2 activity, western blot). Although ACE2 mRNA in both investigated species showed the highest expression in the ileum, the mouse organ exceeded rat ACE2, as also demonstrated in the kidney and colon. Corresponding to mRNA, ACE2 activity was highest in the ileum and mouse kidney but weak in the rat kidney, which was also confirmed by immunohistochemistry. Contrary to mRNA, we found weak activity in the lung of both species. Our data demonstrate a tissue- and species-specific pattern for ACE2 under physiological conditions.


Subject(s)
Carboxypeptidases/metabolism , Angiotensin-Converting Enzyme 2 , Animals , Carboxypeptidases/analysis , Carboxypeptidases/genetics , Ileum/enzymology , Immunohistochemistry , Kidney/enzymology , Lung/enzymology , Mice , Mice, Inbred C57BL , Peptidyl-Dipeptidase A , RNA, Messenger/analysis , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Tissue Distribution
20.
J Neuropathol Exp Neurol ; 63(6): 610-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15217089

ABSTRACT

Neurons of the hippocampal dentate gyrus selectively undergo programmed cell death in patients suffering from bacterial meningitis and in experimental models of pneumococcal meningitis in infant rats. In the present study, a membrane-based organotypic slice culture system of rat hippocampus was used to test whether this selective vulnerability of neurons of the dentate gyrus could be reproduced in vitro. Apoptosis was assessed by nuclear morphology (condensed and fragmented nuclei), by immunochemistry for active caspase-3 and deltaC-APP, and by proteolytic caspase-3 activity. Co-incubation of the cultures with live pneumococci did not induce neuronal apoptosis unless cultures were kept in partially nutrient-deprived medium. Complete nutrient deprivation alone and staurosporine independently induced significant apoptosis, the latter in a dose-response way. In all experimental settings, apoptosis occurred preferentially in the dentate gyrus. Our data demonstrate that factors released by pneumococci per se failed to induce significant apoptosis in vitro. Thus, these factors appear to contribute to a multifactorial pathway, which ultimately leads to neuronal apoptosis in bacterial meningitis.


Subject(s)
Apoptosis/physiology , Hippocampus/cytology , Neurons/cytology , Streptococcus pneumoniae , Animals , Caspase 3 , Caspases/metabolism , Culture Media/pharmacology , Hippocampus/drug effects , Hippocampus/enzymology , Hippocampus/microbiology , Immunohistochemistry , Meningitis, Bacterial/microbiology , Meningitis, Bacterial/pathology , Neurons/drug effects , Neurons/enzymology , Neurons/microbiology , Organ Culture Techniques , Rats , Rats, Wistar , Staurosporine/pharmacology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/growth & development
SELECTION OF CITATIONS
SEARCH DETAIL